Roche Is Joining The Obesity Party But Questions Remain

cagkansayin/iStock via Getty Images And from Carmot's 4-week data release last year, we know that 4-week efficacy was in the ballpark of Viking's VK2735 – absolute weight loss of 8.4% for CT-388 at its highest dose versus 7.8% for the highest VK2735 dose in its 4-week trial. Roche Holding (OTCQX:RHHBY) announced positive topline results from the phase 1b trial of its obesity candidate CT-388 this week and its share price received a 4% boost on the day of the announcement. The results look strong with 18.8% ...